Dashboard
1
High Management Efficiency with a high ROCE of 13.62%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 14.04
3
High Debt company with Weak Long Term Fundamental Strength
4
With ROE of 10.90%, it has a Very Attractive valuation with a 1.73 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
EUR 51,912 Million ()
16.00
NA
0.00%
0.30
11.08%
1.79
Revenue and Profits:
Net Sales:
5,255 Million
(Quarterly Results - Jun 2025)
Net Profit:
655 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.94%
0%
8.94%
6 Months
3.78%
0%
3.78%
1 Year
-16.15%
0%
-16.15%
2 Years
-24.86%
0%
-24.86%
3 Years
-32.68%
0%
-32.68%
4 Years
-44.1%
0%
-44.1%
5 Years
-13.1%
0%
-13.1%
Merck KGaA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.20%
EBIT Growth (5y)
8.73%
EBIT to Interest (avg)
14.04
Debt to EBITDA (avg)
1.36
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.59
Tax Ratio
21.40%
Dividend Payout Ratio
34.44%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
13.62%
ROE (avg)
13.24%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.73
EV to EBIT
12.37
EV to EBITDA
8.68
EV to Capital Employed
1.57
EV to Sales
2.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.74%
ROE (Latest)
10.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 6 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
5,255.00
5,280.00
-0.47%
Operating Profit (PBDIT) excl Other Income
1,534.00
1,650.00
-7.03%
Interest
79.00
78.00
1.28%
Exceptional Items
-93.00
-51.00
-82.35%
Consolidate Net Profit
655.00
738.00
-11.25%
Operating Profit Margin (Excl OI)
204.90%
222.90%
-1.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.47% vs -2.55% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -11.25% vs 10.31% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
21,156.00
20,993.00
0.78%
Operating Profit (PBDIT) excl Other Income
6,168.00
5,825.00
5.89%
Interest
211.00
255.00
-17.25%
Exceptional Items
-674.00
-471.00
-43.10%
Consolidate Net Profit
2,786.00
2,834.00
-1.69%
Operating Profit Margin (Excl OI)
206.20%
192.60%
1.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.78% vs -5.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -1.69% vs -15.12% in Dec 2023
About Merck KGaA 
Merck KGaA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






